A case of visual impairment due to HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia-M2 subtype.

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2024-12-01 Epub Date: 2024-09-30 DOI:10.1007/s00277-024-06030-1

Yan-Sha Pan, Hao Li, Min Yang, Chang-Ling Zhang, Lan Xiao, Chun-Yan Liu, Xue-Yan Deng, Xiu-Mei Xu, You Yang, Wen-Jun Liu

引用次数: 0

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a crucial treatment option for children with M2 subtype acute myeloid leukemia (AML). Human herpesvirus 6 (HHV-6) encephalitis following transplantation is a rare postoperative complication, with a poor prognosis and a high fatality rate in allo-HSCT recipients. In this report, a juvenile patient with AMLwas successfully treated after developing visual impairment as a result of HHV-6B encephalitis during allo-HSCT therapy. HHV-6 encephalitis-associated visual impairment after transplantation is rare, and clinical diagnosis and treatment are challenging, requiring more attention in the future.

查看原文本刊更多论文

一例儿童急性髓性白血病-M2亚型异体造血干细胞移植后因HHV-6脑炎导致的视力障碍。

异基因造血干细胞移植（allo-HSCT）是治疗M2亚型急性髓性白血病（AML）患儿的重要方法。移植后人类疱疹病毒6（HHV-6）脑炎是一种罕见的术后并发症，在异体造血干细胞移植受者中预后较差，致死率较高。在本报告中，一名患有急性髓细胞白血病的青少年患者在接受allo-HSCT治疗期间因患HHV-6B脑炎而导致视力障碍，并成功接受了治疗。移植后HHV-6脑炎相关性视力损伤非常罕见，临床诊断和治疗具有挑战性，需要在未来给予更多关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.